GLPwatch
Papers (10410)
Page 140 of 174, ranked by citation count.
- Liraglutide: can it make a difference in the treatment of type 2 diabetes?
- [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
- Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.
- Glycemia shifts pancreatic islet rhythmicity by influencing interactions between δ cells and α cells.
- Letter by Weir Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity".
- CORRECTION: Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide?
- Once-weekly glucagon-like peptide 1 receptor agonists.
- New Drug for Type 2 Diabetes.
- Research digest: pioneering an oral GLP-1 receptor agonist.
- Automated production of [<sup>68</sup>Ga]Ga-DOTA-exendin-4 via fractionated radionuclide generator elution on a cassette based synthesis module.
- Semaglutide Hype or Hope: Evidence-based Review in Diabesity.
- Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes.
- Cost effectiveness analysis of six non insulin agents for type 2 diabetes in Iran using a patient level simulation with UKPDS OM2.
- Glucagon-like Peptide-1 receptor agonist use is not associated with increased reoperation risk following rotator cuff repair.
- Highlights From AHA 2023-New Risk Calculator, Semaglutide and CVD, and More.
- Choosing injectable therapy: The metabolic fulcrum.
- The metabolic effect of combined liraglutide treatment and lifestyle modification on obese adolescents in a tertiary center, Riyadh.
- Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide.
- Once-Weekly Semaglutide with Lifestyle Intervention Results in Clinically Significant Weight Loss.
- Liraglutide in the management of obesity: real world data (Portugal).
- Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China.
- GLP-1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk.
- Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II.
- Combined effect of continuous glucose monitoring and semaglutide: analysis of administrative claims.
- Functional enhancement of transplanted islets by Extendin-4.
- Synthesis of the extracellular domain of GLP-1R by chemical and biotechnological approaches.
- Formulation and characterization of exenatide-loaded PLGA microspheres prepared by coacervation.
- [Basal insulin degludec - liraglutide fixed ratio combination (Xultophy®)].
- Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center.
- Differential effects of the anti-obesity drug tirzepatide on adipose tissues: Brown fat as a key target.
- Semaglutide (Ozempic) for weight loss.
- Comparative study of dulaglutide single-use pen Ateos versus insulin degludec FlexTouch on learning and mock administration time in Japanese patients with type 2 diabetes mellitus - a <i>post-hoc</i> analysis.
- Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.
- Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements.
- Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide.
- In adults with obesity without diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
- Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few.
- Liraglutide ameliorates intrauterine adhesion by inhibiting NF-κb phosphorylation and reducing epithelial-mesenchymal transition.
- Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.
- Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for Diabetes.
- Liraglutide as a novel therapeutic for overweight in canines: A clinical study.
- The effect of liraglutide, a GLP-1 analog, on indomethacin-induced gastric ulcers in diabetic rats.
- Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular-kidney-metabolic stage progression: a real-world cohort study.
- Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
- Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice.
- Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis.
- Exendin-4 increases the firing activity of hippocampal CA1 neurons through TRPC4/5 channels.
- Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.
- Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population.
- The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation.
- Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney Disease.
- Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide.
- Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study.
- Semaglutide Associated With Less Insulin Need in Early Type 1 Diabetes.
- Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database.
- Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
- Effects of tryptophan-selective lipidated glucagon-like peptide 1 (GLP-1) peptides on the GLP-1 receptor.
- [The glucagon-like peptide-1 receptor-agonist semaglutide].
- Short-Term Weight Loss Outcomes of 1.0 mg Semaglutide Therapy Initiated 6 Months After Sleeve Gastrectomy.